

Application No.: 09/245,198
Amendment and Reply dated January 22, 2004
In response to Examiner's Office Action dated July 22, 2003

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Please cancel claims 11-25, 27 and 32-35 without prejudice.

Listing of Claims

Claim 1 (previously presented): A substantially pure nucleic acid comprising consecutive nucleotides that encode a human TRELL polypeptide, wherein said TRELL polypeptide comprises the amino acid sequence of SEQ ID NO:4.

Claim 2 (previously presented): A substantially pure nucleic acid comprising consecutive nucleotides that encode TRELL, said nucleic acid consisting essentially of SEQ ID NO:1 or SEQ ID NO:3.

Claim 3 (previously presented): A substantially pure nucleic acid consisting essentially of SEQ ID NO:1 or SEQ ID NO:3, said nucleic acid encoding a polypeptide, said polypeptide consisting essentially of SEQ ID NO:2 or SEQ ID NO:4.

Application No.: 09/245,198

Amendment and Reply dated January 22, 2004

In response to Examiner's Office Action dated July 22, 2003

Claim 4 (previously presented): A substantially pure nucleic acid that hybridizes under stringent conditions to SEQ ID NO:3, wherein said stringent conditions comprise washing steps using 2X SSC, 0.1% SDS at 65°C, and wherein said nucleic acid encodes a TREL polypeptide of SEQ ID NO:4, or a soluble fragment thereof, that is capable of binding to a cell selected from the group consisting of:

- a) a K562 promyelocytic cell;
- b) a THP-1 monocytic leukemia cell;
- c) an HT29 colon adenocarcinoma cell;
- d) a 293 embryonic kidney cell; and
- e) a Cos kidney fibroblast cell.

Claim 5 (previously canceled).

Claim 6 (previously presented): The nucleic acid of claim 1 operably linked to an expression control sequence.

Claim 7 (previously presented): The nucleic acid of claim 6 comprising SEQ ID NO:3.

Application No.: 09/245,198
Amendment and Reply dated January 22, 2004
In response to Examiner's Office Action dated July 22, 2003

Claim 8 (previously presented): A host cell transformed with the nucleic acid of claim 6 or 7.

Claim 9 (previously canceled).

Claim 10 (currently amended): A method for producing substantially pure TRELL polypeptide comprising the steps of culturing the host cell of claim 8 and isolating TRELL polypeptide from said transformed host cell to obtain substantially pure TRELL polypeptide.

Claims 11-25 (canceled).

Claim 26 (previously canceled).

Claim 27 (canceled).

Claim 28 (currently amended): A method of expressing a TRELL polypeptide in an animal cell culture comprising the steps of:

introducing a vector comprising a nucleic acid molecule having consecutive nucleotides that encode said TRELL polypeptide into said cell culture, wherein said TRELL polypeptide comprises the amino acid sequence of SEQ ID

Application No.: 09/245,198

Amendment and Reply dated January 22, 2004

In response to Examiner's Office Action dated July 22, 2003

NO:4, or a soluble fragment thereof that is capable of binding to a cell selected from the group consisting of:

- a) a K562 promyelocytic cell;
- b) a THP-1 monocytic leukemia cell;
- c) an HT29 colon adenocarcinoma cell;
- d) a 293 embryonic kidney cell; and
- e) a Cos kidney fibroblast cell; and

allowing said cell culture to live under conditions wherein said nucleic acid molecule is expressed in said cell culture.

Claim 29 (previously canceled).

Claim 30 (previously presented): The method of claim 28 wherein said animal cell culture is a an insect cell culture or a mammalian cell culture.

Claim 31 (previously presented): The method of claim 28 wherein said vector is a virus or a plasmid.

Claims 32-35 (canceled).

Application No.: 09/245,198
Amendment and Reply dated January 22, 2004
In response to Examiner's Office Action dated July 22, 2003

Claims 36-38 (previously canceled).

Claim 39 (previously presented): A substantially pure nucleic acid, consisting essentially of consecutive nucleotides that encode a TRELl polypeptide having the amino acid sequence of SEQ ID NO:2.

Claim 40 (previously presented): A substantially pure nucleic acid, comprising consecutive nucleotides that encode a human TRELl polypeptide, wherein said nucleic acid comprises SEQ ID NO:3.

Claim 41 (previously presented): The nucleic acid of claim 4, wherein said soluble fragment of said TRELl polypeptide comprises an amino-terminus that begins between amino acid numbers 81 and 139 of SEQ ID NO:4.

Claim 42 (previously presented): The nucleic acid of claim 41, wherein said soluble fragment of said TRELl polypeptide comprises amino acid numbers 81 to 284 of SEQ ID NO:4.

Claim 43 (previously presented): The method of 30, wherein said mammalian cell culture is a human cell culture.

Claim 44 (previously presented): A method of expressing a TREL polypeptide in an animal cell culture, comprising the steps of:

introducing a vector comprising a nucleic acid molecule comprising consecutive nucleotides encoding a TREL polypeptide into said cell culture, wherein said TREL polypeptide consists essentially of the amino acid sequence of SEQ ID NO:2; and

allowing said cell culture to live under conditions wherein said nucleic acid molecule is expressed in said cell culture.

Claim 45 (previously presented): The method of claim 44, wherein said animal cell culture is an insect cell culture or a mammalian cell culture.

Claim 46 (previously presented): The host cell of claim 8, wherein said host cell is a mammalian cell.

Claim 47 (previously presented): The host cell of claim 46, wherein said mammalian cell is a human cell.